PMS32 ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)75172-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)75172-X/fulltext
Title :
PMS32 ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)75172-X&doi=10.1016/S1098-3015(10)75172-X
First page :
Section Title :
Open access? :
No
Section Order :
1096